Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M182,446Revenue (TTM) $M49,436Net Margin (%)13.5Altman Z-Score2.6
Enterprise Value $M206,173EPS (TTM) $2.8Operating Margin %16.7Piotroski F-Score5
P/E(ttm)28.3Beneish M-Score-2.7Pre-tax Margin (%)15.7Higher ROA y-yN
Price/Book2.410-y EBITDA Growth Rate %-2.5Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %-3.9Current Ratio1.1Lower Leverage y-yN
Price/Free Cash Flow23.0y-y EBITDA Growth Rate %-0.7ROA % (ttm)5.1Higher Current Ratio y-yY
Dividend Yield %3.5PEG--ROE % (ttm)9.0Less Shares Outstanding y-yY
Payout Ratio %96.0Shares Outstanding M2,374ROIC % (ttm)7.1Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NVS is held by these investors:



NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15413.87view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Novartis Has Bright Future Feb 01 2017 
    2 Top Health Care Dividend Stocks Jan 12 2017 
    7 Stocks With Low P/S Ratios Jan 11 2017 
    Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
    Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
    Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
    The Pharmaceutical Sector Looks Attractive Oct 12 2016 
    Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
    Novartis Is Surviving Oct 03 2016 
    A Double Dose of Trouble at Novartis Sep 22 2016 

    More From Other Websites
    This Keeps Driving Sanofi’s Growth Feb 20 2017
    Blog Coverage Ionis Pharma Closed on its Collaboration Agreement with Novartis Following Clearance... Feb 17 2017
    Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback Feb 16 2017
    GlaxoSmithKline’s Valuation Compared to Its Peers Feb 16 2017
    Bristol-Myers: Don't Bet on a Pfizer Acquisition Feb 15 2017
    Bristol-Myers Squibb: Takeover Target? Feb 14 2017
    4Q16 Performance of GlaxoSmithKline’s Business Segments Feb 14 2017
    Novartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education Feb 14 2017
    These N.Y.C.-area doctors received the most payments from drug and device makers Feb 14 2017
    10 Most Diverse Companies In The US Feb 10 2017
    UBS Makes First Big 2017 Addition to Dividend Rulers Stocks List Feb 09 2017
    Propeller Health Enters into Collaboration to Connect Breezhaler™ Devices to the Propeller... Feb 08 2017
    Novartis’s Valuation after the 4Q16 Results Feb 03 2017
    Why the Majority of Analysts Deem Novartis a ‘Buy’ Feb 03 2017
    Novartis’s Financial Guidance and Priorities for 2017 Feb 03 2017
    Novartis’s Recent Developments Feb 02 2017
    Novartis (NVS) Votubia Gets EU Approval for Label Expansion Feb 02 2017
    Inside Novartis’s Eye Care Performance in 4Q16 Feb 02 2017
    Inside Novartis’s Generics Performance in 4Q16 Feb 02 2017
    Novartis says court battle will delay its Enbrel copy until 2018 at least Jan 25 2017
    Novartis launches $5 billion share buyback, mulls Alcon spin-off Jan 25 2017
    Novartis beats 4Q profit forecasts Jan 25 2017
    Novartis to buy back $5 bn in shares Jan 25 2017
    Drug firm Novartis mulls options for Alcon amid flat 4Q net Jan 25 2017
    Novartis CEO: "The bigger the target, the higher the premium" Jan 25 2017
    Novartis to buy back $5 bn in shares Jan 24 2017
    CSL shares jump on profit upgrade Jan 19 2017
    CSL shares rally on profit guidance hike Jan 18 2017
    Trump tax cuts could mean more Novartis investment in U.S. Jan 18 2017
    Trump tax cuts could mean more Novartis investment in U.S Jan 18 2017
    Trump tax cuts could mean more Novartis investment in U.S Jan 18 2017
    Novartis joins forces with Ionis on cardiovascular treatments Jan 06 2017
    Novartis joins forces with Ionis on cardiovascular treatments Jan 06 2017
    Out-licensing of COPD products in the US Dec 21 2016
    Licensing agreement signed for the launch of Utibron/Seebri in the US Dec 21 2016
    Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc. Dec 20 2016
    Novartis says reaches agreement to buy Texas-based Encore Vision Dec 20 2016
    Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new... Dec 19 2016
    Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset... Dec 16 2016
    Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and... Dec 16 2016
    Novartis says buys Ziarco Group to expand skin care portfolio Dec 16 2016
    Novartis says buys Ziarco Group to expand skin care portfolio Dec 16 2016
    Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited Dec 16 2016
    Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain... Nov 21 2016
    Novartis acquires US pharma research firm Selexys Pharmaceuticals Nov 21 2016
    Novartis commends publication of major report which recommends broad use of dual bronchodilators to... Nov 21 2016
    Novartis acquires US pharma research firm Selexys Pharmaceuticals Nov 20 2016
    Novartis backs off from 2016 date for testing Google autofocus lens Nov 18 2016
    Novartis backs off from 2016 date for testing Google autofocus lens Nov 18 2016
    Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood... Nov 16 2016
    New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and... Nov 15 2016
    The Novartis house that Vasella built gets extreme makeover Nov 14 2016
    Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML... Nov 14 2016
    Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3... Nov 14 2016
    Novartis improves ranking in 2016 Access to Medicine Index Nov 13 2016
    Novartis, Pfizer cut prices to win UK approval for cancer drugs Nov 09 2016
    Novartis, Pfizer cut prices to win UK approval for cancer drugs Nov 09 2016
    Astex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (Ribociclib) Plus... Nov 01 2016
    Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2-... Nov 01 2016
    Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration;... Oct 25 2016
    Big Pharma vs Big Pharma in court battles over biosimilar drugs Oct 03 2016
    Big Pharma vs Big Pharma in court battles over biosimilar drugs Oct 02 2016
    Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
    Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
    Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
    Novartis bid to sell new biosimilar crimped by U.S. court battles Aug 31 2016
    Turkey's investigation into drugmaker Novartis 'ongoing' -official Aug 17 2016
    Turkey's investigation into drugmaker Novartis 'ongoing' -official Aug 17 2016
    Turkey's investigation into drugmaker Novartis 'ongoing' - official Aug 17 2016
    Novartis says bribe allegations in Turkey groundless, matter closed Aug 12 2016
    Novartis could face S.Korea sales ban amid corruption allegations: media Aug 11 2016
    AstraZeneca a bid target again? CEO says someone may spot value Jul 28 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)